Median duration of the chronic phase of chronic myelogenous leukemia (CML) is 3 years;
less than 20% of patients have a chronic phase greater than 7 years. It is unknown whether …

The bcr-abl RNA transcript is the molecular counterpart of the Philadelphia chromosome
and is detectable by an extremely sensitive polymerase chain reaction assay in most …

We report the results of consecutive tests in nine BCR‐ABL‐positive ALL patients by one‐
step and two‐step (nested primer) reverse transcriptase‐polymerase chain reaction (RT …

Provides information on methodologies in detecting minimal residual disease (MRD) in
acute myeloid leukemia. Processes involved in florescence in situ hybridization; Nucleic …

For many years hematologists have used the microscope to identify a complete remission of
leukemia after treatment with chemotherapy. In a hematologic complete remission, we know …

Background and objective: Accurate quantification of BCR-ABL mRNA is of critical
importance for managing chronic myeloid leukemia (CML) patients receiving Imatinib …

Nested PCR (NPCR), a two-step procedure in which the products of a first PCR
using'outer'primers are reamplified using'inner primers', has been successfully used to test …

Chronic myelogenous leukemia (CML) is a myeloproliferative disorder associated with the
Philadelphia chromosome (Ph1) in more than 95% of these patients. The Ph1 and the …

We investigated the significance of p185BCR/ABL expression in patients with chronic
myelogenous leukaemia (CML) in relation to disease features, therapy and outcome …

The characteristic genetic exchange in chronic myeloid leukemia (CML) is the fusion of the
ABL proto-oncogene and a specific part of the BCR or phl gene. Detection of this exchange …